Medarex to Receive Milestone Payment from Amgen
13th Nov 2006, 16:15 GMT
Medarex expects to receive an undisclosed milestone payment from its licensing partner, Amgen for the advancement of an antibody into clinical trials.
Medarex to Receive Milestone Payment from Amgen related news:
- Medarex to Get Milestone From Amgen — Financial News News from StratCenter.com
- Medarex to Get Milestone from Amgen and Illumina to Buy Solexa For About $600M — Financial News USA (OTC: FNWU)
- Spectrum Pharmaceuticals gets $5M milestone payment — Latest news from Los Angeles Business from bizjournals
- Spectrum Pharmaceuticals gets $5M milestone payment, settles with GlaxoSmithKline — bizjournals.com Health Care:Pharmaceuticals headlines
- Spectrum Pharmaceuticals to Receive $5 Million Milestone Payment From PAR Pharmaceutical for Sumatriptan Injection — RedOrbit News - Health
- Spectrum Pharmaceuticals to Receive $5 mln Milestone Payment From PAR Pharmaceutical for Sumatriptan Injection — Pharmaceuticals News from StratCenter.com
- First Data to Expand Payment Services in China — CRM Buyer
- Amgen Releases Long-Term Enbrel Data — Bio-Technology News from StratCenter.com
- Amgen arthritis drug shows sustained safety and efficacy — Pharmaceutical Business Review Latest News
- National Kidney Foundation Launches New Phase of Kidney Early Evaluation Program, Names Amgen KEEP Principal Sponsor — Nephrology/ Dialysis News from StratCenter.com
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Arqule Early Cancer Study Shows Progress
- Tanox shares soar in wake of Genentech buyout